Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

60.54USD
11:54am EST
Change (% chg)

$-0.60 (-0.98%)
Prev Close
$61.14
Open
$60.65
Day's High
$61.09
Day's Low
$60.39
Volume
693,329
Avg. Vol
1,827,140
52-wk High
$64.44
52-wk Low
$46.32

BMY.N

Chart for BMY.N

About

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities... (more)

Overall

Beta: 0.31
Market Cap(Mil.): $101,417.60
Shares Outstanding(Mil.): 1,658.78
Dividend: 0.37
Yield (%): 2.42

Financials

  BMY.N Industry Sector
P/E (TTM): 50.79 39.97 40.64
EPS (TTM): 1.20 -- --
ROI: -- 18.85 18.12
ROE: -- 19.60 18.97
Search Stocks

FDA approves Bristol-Myers, J&J HIV pills

- The U.S. Food and Drug Administration on Thursday approved two fixed-dose HIV pills that combine protease inhibitors - one made by Bristol-Myers Squibb Co and the other by Johnson & Johnson - both with a boosting agent produced by Gilead Sciences Inc.

29 Jan 2015

U.S. FDA approves Bristol-Myers' HIV drug

Jan 29 - The U.S. Food and Drug Administration has approved the sale of Evotaz, a once-daily combination pill to treat HIV made by Bristol-Myers Squibb Co, the company said on Thursday.

29 Jan 2015

RPT-UPDATE 2-U.S. multinationals hit hard by strong dollar, to bleed further into 2015

* Strong dollar may cut up to $12 bln from Q4 U.S. revenue -FireApps

27 Jan 2015

UPDATE 1-Bristol-Myers issues cautious 2015 forecast due to strong dollar

Jan 27 - Bristol-Myers Squibb Co on Tuesday said profits could fall as much as 16 percent in 2015, a worse forecast than Wall Street had expected, as the stronger dollar takes a toll on U.S. drugmakers.

27 Jan 2015

Bristol-Myers quarterly profit beats forecasts

Jan 27 - Bristol-Myers Squibb Co reported higher-than-expected quarterly earnings, helped by surprisingly strong sales of its hepatitis C drugs and its Eliquis blood clot preventer.

27 Jan 2015

What to Watch in the Day Ahead - Tuesday, Jan. 27

(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users can register at RT/DAY/US. All times in ET/GMT) Apple Inc is expected to report one of its strongest quarters ever, helped by strong unit sales of its larger-screen iPhone 6 and 6 Plus. The new iPhones are helping Apple chip away at Samsung Electronics' dominant position in its home turf of South K

26 Jan 2015

Bristol-Myers taps insider Caforio as next CEO

NEW YORK - U.S. drugmaker Bristol-Myers Squibb Co on Tuesday said Chief Operating Officer Giovanni Caforio will replace Lamberto Andreotti as chief executive on May 5, in another selection of a long-time insider to lead the company.

20 Jan 2015

UPDATE 1-Bristol-Myers taps insider Caforio as next CEO

NEW YORK, Jan 20 - U.S. drugmaker Bristol-Myers Squibb Co on Tuesday said Chief Operating Officer Giovanni Caforio will replace Lamberto Andreotti as chief executive on May 5, in another selection of a long-time insider to lead the company.

20 Jan 2015

Bristol-Myers taps insider Caforio as next CEO

Jan 20 - U.S. drugmaker Bristol-Myers Squibb Co on Tuesday said Chief Operating Officer Giovanni Caforio will replace Lamberto Andreotti as chief executive on May 5, as the company again tapped a long-time insider to lead it.

20 Jan 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $101.01 -1.37
Pfizer Inc. (PFE.N) $31.49 -0.34
Merck & Co., Inc. (MRK.N) $61.08 -1.01
Sanofi SA (SASY.PA) €82.00 -0.26
AstraZeneca plc (AZN.L) 4,743.00p -18.50
GlaxoSmithKline plc (GSK.L) 1,467.00p -25.50
Eli Lilly and Co (LLY.N) $72.30 +0.19

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks